Clinical trials: Blood-Borne Infections
HIV/AIDS, HIV Prevention
Tenofovir Rectal Douche to Prevent HIV Transmission
DREAM-03 is an early phase-1, open label study to compare the safety, pharmacokinetics (PK), pharmacodynamics (PD), and acceptability of 3 sequences of tenofovir (TFV) and non-medicated douches.
- Trial name
- DREAM-03 (NCT04016233)
- Testing
- Tenofovir douche
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Mental Health Issue, Hiv
Healthy Mothers: an Intervention to Support Perinatal Women Living With HIV in Kenya
The investigators will recruit 40 pregnant women living with HIV divided into 2 groups (n=20 intervention group, n=20 control group).
- Conditions
- Mental Health Issue, Hiv, Breastfeeding, Exclusive
- Trial name
- NCT05219552
- Testing
- personalized lactation support
- Where
- 2 sites in Kenya
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Cytomegalovirus Retinitis, HIV Infections
A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS
To evaluate the safety and tolerance of long-term ganciclovir (DHPG) therapy for newly diagnosed macular threatening Cytomegalovirus (CMV) retinitis in AIDS patients.
- Trial name
- NCT00002034
- Testing
- Zidovudine, Ganciclovir
- Where
- 9 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
HIV, AIDS
HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University
Human Immunodeficiency Virus (HIV) infected patients in the HIV registries of Johns Hopkins University, University of North Carolina and Vanderbilt University will be followed in the routine clinical care to estimate the rates of…
- Trial name
- NCT01339416
- Volunteers
- 8,202 people
- Sponsor
- ViiV Healthcare
Hepatitis C
Hepatitis C-Video vs. Brochure Education Delivery
The purpose of this study is to determine the most effective way to give patients information regarding hepatitis C virus infection.
- Trial name
- NCT04204447
- Testing
- Hepatitis C Educational Brochure, Hepatitis C Educational Video
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- State University of New York at Buffalo
Hiv
DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)
The goal of this pilot, phase 2, single-arm, clinical trial is to assess the antiretroviral combination Doravirine (DOR)/Lamivudine (3TC)/Tenofovir Disproxyl Fumarate (TDF) in participants with suppressed HIV who previously…
- Trial name
- DOR (NCT06034938)
- Testing
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
- Where
- 4 sites in France
- Volunteers
- 32 people
- Sponsor
- University Hospital, Caen
HIV/AIDS
A Peer-Led Intervention to Improve Postpartum Retention in HIV Care
The purpose of this study is to test the efficacy of a theory-driven peer intervention for pregnant and postpartum women living HIV.
- Trial name
- NCT04168008
- Testing
- WISH Adherence, WISH Parenting
- Where
- 7 sites in United States
- Volunteers
- 151 people
- Sponsor
- University of Pennsylvania
Infection, Human Immunodeficiency Virus, HIV Infections
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected antiretroviral experienced, integrase-naïve…
- Trial name
- SAILING (NCT01231516)
- Testing
- GSK1349572, Raltegravir
- Where
- 180 sites in United States, Argentina and 18 more
- Volunteers
- 724 people
- Sponsor
- ViiV Healthcare
HIV Infection
MAPS PrEP Van Study
For this study the investigators aim to see if giving participants an oral HIV prevention medication on a medical van, is a good option of care for individuals who inject drugs and/or are sexually active and therefore at a higher…
- Trial name
- MAPS PrEP (NCT06908252)
- Testing
- Pre-Exposure Prophylaxis (PrEP)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Duke University
HCV, HBV
HCV, HBV, HIV Testing During Consultation With Anesthesiologist
The aim of the study is to assess the feasibility of HCV, HBV, HIV testing (according to the national guidelines) during consultation with Anesthesiologist before a planned surgery in Lariboisiere Hospital, Paris, France.
- Conditions
- HCV, HBV, Hiv
- Trial name
- SAHARA (NCT04286347)
- Testing
- HCV, HBV, HIV tests
- Where
- France
- Volunteers
- 363 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Tuberculosis, Pulmonary, HIV/AIDS
RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection
Although tuberculosis is a treatable disease, it is currently the infectious disease with the highest mortality in the world. It is estimated that one-third of the world's population is infected.
- Trial name
- RIPENACTB (NCT03281226)
- Testing
- RIPE (2m) and RI (4m), RIPE+NAC (2m) and RI (4m)
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Meningitis, Cryptococcal, HIV Infections
Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS
To compare the safety and effectiveness of a new drug, fluconazole, with that of the usual therapy, amphotericin B, in the prevention of a relapse of cryptococcal meningitis (CM) in patients with AIDS who have been successfully…
- Trial name
- NCT00001017
- Testing
- Fluconazole, Amphotericin B
- Where
- 28 sites in United States
- Volunteers
- 330 people
- Sponsor
- Pfizer
HIV Infections
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers
To evaluate the safety and immunogenicity of ALVAC-HIV MN120TMG (vCP205) in comparison to ALVAC-RG rabies glycoprotein (vCP65) as a control when administered in HIV-1 negative volunteers.
- Trial name
- NCT00001055
- Testing
- ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
- Where
- 6 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic
Gilead Sustained Virologic Response (SVR) Registry
This Registry is designed to provide long term clinical and virologic follow up in participants who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored hepatitis C virus (HCV)…
- Trial name
- NCT01457755
- Where
- 325 sites in United States, Australia and 15 more
- Volunteers
- 6,625 people
- Sponsor
- Gilead Sciences
Diphtheria, Tetanus
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
The project goal is to conduct a randomized controlled trial (RCT) to test whether mobile phone short message system (SMS) reminders, either with or without mobile-phone based travel subsidies will improve timeliness, coverage…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- m-SIMU (NCT01878435)
- Testing
- SMS reminder, Travel subsidy, Travel subsidy 2
- Where
- Kenya
- Volunteers
- 2,018 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV
Study of SystemCHANGE-HIV
The purpose of this study is to assess a new behavioral intervention to help how people living with HIV/AIDS practice self-management skills.
- Trial name
- NCT01256814
- Testing
- SystemCHANGE-HIV
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Case Western Reserve University
HIV-Infections
TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients
This trial is designed to assess the swallowability of uncoated and film-coated 200 mg etravirine tablets in HIV-1 infected patients.
- Trial name
- NCT01090648
- Testing
- etravirine
- Volunteers
- 49 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults
The purpose of this study is to see if a certain combination of anti-HIV drugs is safe and effective in HIV-infected patients. The drug combination includes a tablet containing lamivudine and zidovudine (called Combivir) plus…
- Trial name
- NCT00004585
- Testing
- Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Glaxo Wellcome
Hiv
Multi-product PrEP Delivery to Young Women Seeking Reproductive Health Services and Coverage of HIV Prevention
Following on the heels of large implementation science projects that participated in the launch of widespread daily oral PrEP availability, investigators will launch and study the integration of novel PrEP products - beginning…
- Trial name
- PrEMIA (NCT07076043)
- Testing
- Multiple Product PrEP Program, Routine Oral PrEP
- Where
- Kenya
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
HIV Infections
3TC (Lamivudine; GR109714X) Open-Label Program
To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies.
- Trial name
- NCT00002108
- Testing
- Lamivudine, Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.